The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 28, 2023
Filed:
Feb. 02, 2017
Applicant:
University of Massachusetts, Boston, MA (US);
Inventors:
Miguel Sena Esteves, Westford, MA (US);
Ana Rita Batista, Worcester, MA (US);
Sourav Roy Choudhury, Newton, MA (US);
Assignee:
University of Massachusetts, Boston, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); A61K 31/7016 (2006.01); A61K 31/351 (2006.01); A61K 47/64 (2017.01); C12N 15/79 (2006.01); C12N 15/86 (2006.01); C07K 14/775 (2006.01); A61K 47/62 (2017.01); A61K 31/5415 (2006.01); C12N 15/63 (2006.01); A61K 38/17 (2006.01); A61K 9/00 (2006.01); C12N 15/64 (2006.01); A61K 31/4706 (2006.01); A61K 47/42 (2017.01); C07K 5/083 (2006.01);
U.S. Cl.
CPC ...
A61K 48/0008 (2013.01); A61K 9/0085 (2013.01); A61K 31/351 (2013.01); A61K 31/4706 (2013.01); A61K 31/5415 (2013.01); A61K 31/7016 (2013.01); A61K 38/1709 (2013.01); A61K 47/42 (2013.01); A61K 47/62 (2017.08); A61K 47/6455 (2017.08); C07K 14/775 (2013.01); C12N 15/63 (2013.01); C12N 15/64 (2013.01); C12N 15/79 (2013.01); C12N 15/86 (2013.01); C07K 5/0808 (2013.01); C07K 2319/00 (2013.01); C07K 2319/33 (2013.01); C12N 2750/14143 (2013.01);
Abstract
The disclosure relates, in some aspects, to compositions and methods for enhanced delivery of a transgene to the central nervous system (CNS) of a subject. In some embodiments, the transgene is delivered by recombinant AAV (rAAV). In some embodiments, the method of enhancing transgene delivery comprises administering a blood brain barrier (BBB)-crossing molecule (e.g., K16ApoE) and an rAAV comprising a transgene to a subject.